CEO Executive AssistantGovernment affairs is a domain where pharma CEOs must be strategically visible without becoming operationally enmeshed. Drug pricing legislation, Medicare negotiation policy, FDA regulatory frameworks, and international market access regulations all have multi-billion dollar implications for pharmaceutical companies. The CEO’s engagement with policymakers, legislators, and regulatory officials carries organizational authority that cannot be replicated at any other level. Yet the operational work of government affairs, including lobbying coordination, regulatory comment letters, policy coalition management, and legislative tracking, is specialized professional work that belongs to a dedicated government affairs team.
This guide establishes the delegation framework that allows pharma CEOs to maintain strategic government affairs engagement while building the organizational capacity to manage policy work at scale.
The VP of Government Affairs as Primary Delegate
The Vice President of Government Affairs or Chief Government Affairs Officer is the CEO’s primary delegate for all government affairs operations. This person should be a seasoned policy professional with deep relationships in relevant regulatory and legislative communities, credibility with trade associations, and the organizational authority to speak for the company on policy matters within defined parameters.
The VP of Government Affairs owns: all legislative monitoring and analysis, lobbying coordination and advocacy strategy, regulatory comment letter drafting and submission, trade association participation and coordination, political action committee management (where applicable), and policy coalition management. The CEO engages through this function, not around it.
The organizational reporting structure matters. Government affairs should have direct CEO access for strategic matters and a clear path to the board’s governance or public affairs committee. If government affairs reports several layers below the CEO, it is structurally positioned to be reactive rather than strategic.
Defining CEO-Level Government Affairs Engagement
The CEO’s government affairs engagement should be reserved for moments where organizational authority and CEO credibility genuinely change the outcome. These moments typically include:
Direct engagement with senior government officials: Meetings with the FDA Commissioner, HHS Secretary, relevant Congressional committee chairs, or equivalent officials in international markets. The CEO’s presence at these meetings signals organizational commitment and enables relationship-level conversation that the VP of Government Affairs cannot replicate.
Industry leadership moments: Participating in PhRMA board activities, speaking at industry policy events where the CEO represents the company’s policy position, and engaging with coalitions on issues of strategic importance to the company.
Crisis policy management: When a congressional investigation, regulatory enforcement action, or major policy shift directly threatens the company, the CEO must be personally engaged in the strategic response, even while the VP of Government Affairs manages the operational dimensions.
Investor-relevant policy disclosures: When a policy development has material implications for company financials, the CEO’s government affairs engagement becomes investor relations territory and must be coordinated with the CFO and Head of IR.
All other government affairs activity, including the hundreds of routine policy engagements that characterize an active government affairs program, belongs to the VP of Government Affairs and their team.
Delegating Regulatory Advocacy
Pharmaceutical companies engage extensively with FDA and other regulatory agencies on policy questions: guidance document comments, regulatory framework consultations, advisory committee participation, and standard-setting processes. This regulatory advocacy work is distinct from the product-specific regulatory submissions managed by Regulatory Affairs.
Regulatory advocacy should be co-owned by the VP of Government Affairs and the Head of Regulatory Affairs, with clear protocols for coordination. The CEO’s regulatory advocacy engagement is limited to: the company’s position on major regulatory framework questions that affect the broader industry, any direct FDA leadership meetings on policy matters (as distinct from product-specific regulatory meetings), and any public statements on regulatory policy.
The detailed work of preparing and submitting comment letters, coordinating regulatory advocacy through trade associations, and monitoring regulatory policy developments is the government affairs team’s domain.
Building the Policy Intelligence System
Effective government affairs delegation requires a policy intelligence system that keeps the CEO informed about relevant policy developments without requiring the CEO to monitor legislative and regulatory activity personally.
The VP of Government Affairs should produce a weekly policy brief for the CEO covering: significant legislative developments affecting the pharmaceutical industry, regulatory agency actions relevant to the company’s product portfolio, international policy developments in key markets, and any policy opportunities or threats that may require CEO-level response.
This brief should be written to inform the CEO’s strategic decision-making and investor communications, not to provide exhaustive policy detail. The CEO reads the brief, asks clarifying questions when needed, and flags any items requiring escalation of CEO-level engagement. The VP of Government Affairs manages all response and monitoring activities.
Delegation to Trade Associations
Pharmaceutical companies participate in multiple industry trade associations: PhRMA, BIO, AdvaMed (for device-adjacent products), and various disease-area and international trade bodies. Managing these relationships is an operational government affairs function, not a CEO function.
The VP of Government Affairs manages: day-to-day trade association liaison, working group participation, position paper development, dues management, and coordination of company positions with trade association advocacy. The CEO’s trade association engagement is limited to: board-level participation in major associations where CEO participation is expected, speaking roles at significant industry events, and relationship investment with trade association leadership on strategic policy matters.
Define the CEO’s annual trade association calendar in advance, with the VP of Government Affairs recommending which events and engagements warrant CEO presence. This prevents the CEO from being pulled into every trade association function while ensuring presence at the genuinely strategic moments.
According to McKinsey research on pharmaceutical government affairs effectiveness, pharmaceutical companies that invest in professional, dedicated government affairs capabilities with appropriate CEO strategic engagement significantly outperform those that rely on CEO-led advocacy without a dedicated professional function. Building and empowering the VP of Government Affairs is the investment that makes this performance difference possible.
Managing International Government Affairs
For pharma companies with global operations, government affairs extends across multiple regulatory and legislative jurisdictions. Managing international government affairs requires both a global coordination function and strong local capabilities in key markets.
The VP of Government Affairs should manage a global government affairs network that includes either employed government affairs professionals or contracted affairs firms in each major market. The CEO’s international government affairs engagement follows the same principles as domestic engagement: strategic relationship investment with senior government officials, presence at significant industry policy moments, and engagement when a policy development has major financial or strategic implications.
Country or regional CEOs or General Managers in international markets typically manage the local government affairs relationships with support from the global government affairs function. The corporate CEO should not be the primary government affairs contact in markets where the company has local leadership.
Coordinating Government Affairs with Other Functions
Government affairs does not operate in isolation. Policy advocacy often intersects with Medical Affairs (clinical evidence support for coverage and reimbursement policy), Regulatory Affairs (regulatory framework policy), Legal (antitrust and compliance implications of policy positions), and Public Relations (communications strategy around policy engagements).
The VP of Government Affairs should have defined coordination protocols with each of these functions. The CEO’s role is to ensure these cross-functional relationships exist and function effectively, not to broker every inter-functional coordination decision.
For context on how government affairs delegation connects to the broader regulatory affairs function, see pharma regulatory affairs, which provides a detailed framework for delegating across regulatory submissions and advocacy functions.
The CEO’s Policy Legacy
Beyond operational delegation, pharma CEOs carry a responsibility for the industry’s long-term policy environment. The decisions made about drug pricing transparency, clinical trial diversity, pandemic preparedness, and access to medicines will shape the regulatory and legislative landscape for decades. The CEO’s most significant government affairs contribution may be thought leadership on these systemic questions, rather than any specific lobbying outcome.
This thought leadership role, expressed through public commentary, congressional testimony on major policy questions, and engagement with policy research institutions, is distinctly a CEO function. It requires the VP of Government Affairs to prepare, brief, and position the CEO for these engagements, but the credibility and organizational authority come from the CEO personally.
See pharma CEO delegation guide for a comprehensive framework connecting government affairs delegation to the full range of pharma CEO external-facing leadership responsibilities.
Building an effective government affairs delegation model protects the CEO’s strategic policy engagement while ensuring that the operational work of advocacy is handled by professionals who can manage it effectively at scale. This combination, strategic CEO visibility and operational professional capability, is what gives pharmaceutical companies the government affairs effectiveness their business requires.
Related Reading
For further context, explore Delegation Guide for Affordable Housing Nonprofit CEOs and Delegation Guide for Automotive CEO: Brand Management.